“…The surface markers CD133, L1CAM, CD44, and the intracellular proteins and transcriptional factors, such as NANOG, NESTIN-neuroepithelial stem cell protein, Bmi1, SOX2, OLIG2, and MYC, overrun with those determined for recognition of NCS, thus challenging the recognition of GSCs in a mingled tumor [ 169 , 179 , 185 ]. Surface proteins (such as CD9, CD15, integrin-α6, enzymatic activity of aldehyde dehydrogenase 1 (ALDH1)) and signaling pathways (such as NOTCH, SHH, WNT/β-catenin, EGFR) are also overexpressed and overlap with those in NCS in terms of maintaining an undifferentiated character, a perpetual self-renewal state and a strong potency in initiating tumor development and proliferation [ 182 , 186 , 187 ]. All these markers reflect the GSCs’ high heterogeneity and try to define the GSCs’ multiple cellular subclones or multipotent microstates, which are inducing strong adaptability and high invasiveness in GBM [ 188 ].…”